{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:39:33Z","timestamp":1769841573348,"version":"3.49.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Besides being expressed on endothelial cells, vascular endothelial growth factor receptors (VEGFRs) are also functional on subsets of leukemias, resulting in autocrine loops that sustain leukemia migration and proliferation. While recent evidence suggests that VEGF supports hematopoietic stem cell survival via an internal loop, the molecular mechanisms whereby autocrine stimulation of VEGFR-2 (KDR) promotes leukemia growth are not well understood. Here we show on acute myeloid primary leukemias and cell lines that VEGF\/KDR autocrine loops operate both internally and externally. First, we demonstrate that KDR is constitutively phosphorylated and located at the nucleus of VEGF-producing leukemias. Treatment with anti-VEGF antibody, which acts externally, blocked KDR nuclear translocation and inhibited nuclear factor \u03ba B (NF-\u03baB; p65 and c-rel) activation. In contrast, a KDR-specific intracellular inhibitor failed to block KDR nuclear translocation, but inhibited the constitutive activation of mitogen activated protein kinase (MAPK)\/Erk and the phosphatidylinositol 3-kinase\/AKT pathways. Notably, treatment with the anti-VEGF antibody alone had little effect on cell survival, while the internal inhibitor induced leukemia apoptosis, and the 2 drugs produced synergistic effects, together and with chemotherapy, reducing cell survival to a larger extent than either agent alone. Our results demonstrate that internal and external VEGF\/KDR autocrine loops regulate leukemia survival via different mechanisms, and suggest that blocking both may have therapeutic potential.<\/jats:p>","DOI":"10.1182\/blood-2003-05-1634","type":"journal-article","created":{"date-parts":[[2004,1,20]],"date-time":"2004-01-20T01:14:24Z","timestamp":1074561264000},"page":"3883-3889","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":133,"title":["Internal and external autocrine VEGF\/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways"],"prefix":"10.1182","volume":"103","author":[{"given":"Susana Constantino Rosa","family":"Santos","sequence":"first","affiliation":[{"name":"From the Angiogenesis Laboratory, CIPM\/Instituto Portugue\u0302s de Oncologia Francisco Gentil (IPOFG), Lisboa, and the Instituto Gulbenkian de Cie\u0302ncia, Oeiras, Portugal."}]},{"given":"Se\u0301rgio","family":"Dias","sequence":"additional","affiliation":[{"name":"From the Angiogenesis Laboratory, CIPM\/Instituto Portugue\u0302s de Oncologia Francisco Gentil (IPOFG), Lisboa, and the Instituto Gulbenkian de Cie\u0302ncia, Oeiras, Portugal."}]}],"member":"234","reference":[{"key":"2020021219282867700_REF1","doi-asserted-by":"crossref","unstructured":"Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13: 9-22.","DOI":"10.1096\/fasebj.13.1.9"},{"key":"2020021219282867700_REF2","unstructured":"Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55: 15-35."},{"key":"2020021219282867700_REF3","doi-asserted-by":"crossref","unstructured":"Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res. 1999;253: 117-130.","DOI":"10.1006\/excr.1999.4707"},{"key":"2020021219282867700_REF4","doi-asserted-by":"crossref","unstructured":"Wu LW, Mayo LD, Dunbar JD, et al. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem. 2000;275: 5096-5103.","DOI":"10.1074\/jbc.275.7.5096"},{"key":"2020021219282867700_REF5","doi-asserted-by":"crossref","unstructured":"Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97: 1427-1434.","DOI":"10.1182\/blood.V97.5.1427"},{"key":"2020021219282867700_REF6","doi-asserted-by":"crossref","unstructured":"Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106: 511-521.","DOI":"10.1172\/JCI8978"},{"key":"2020021219282867700_REF7","doi-asserted-by":"crossref","unstructured":"Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF\/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A. 2001;98: 10857-10862.","DOI":"10.1073\/pnas.191117498"},{"key":"2020021219282867700_REF8","doi-asserted-by":"crossref","unstructured":"Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer. 2002;97: 393-399.","DOI":"10.1002\/ijc.1634"},{"key":"2020021219282867700_REF9","doi-asserted-by":"crossref","unstructured":"Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787\/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm. 2001;16: 359-370.","DOI":"10.1089\/108497801753354267"},{"key":"2020021219282867700_REF10","doi-asserted-by":"crossref","unstructured":"Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417: 954-958.","DOI":"10.1038\/nature00821"},{"key":"2020021219282867700_REF11","doi-asserted-by":"crossref","unstructured":"Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001;276: 3222-3230.","DOI":"10.1074\/jbc.M002016200"},{"key":"2020021219282867700_REF12","doi-asserted-by":"crossref","unstructured":"Issbrucker K, Marti HH, Hippenstiel S, et al. p38 MAP kinase\u2014a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 2003;17: 262-264.","DOI":"10.1096\/fj.02-0329fje"},{"key":"2020021219282867700_REF13","doi-asserted-by":"crossref","unstructured":"Yashima R, Abe M, Tanaka K, et al. Heterogeneity of the signal transduction pathways for VEGF-induced MAPKs activation in human vascular endothelial cells. J Cell Physiol. 2001;188: 201-210.","DOI":"10.1002\/jcp.1107"},{"key":"2020021219282867700_REF14","doi-asserted-by":"crossref","unstructured":"Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol. 2000;60: 1085-1089.","DOI":"10.1016\/S0006-2952(00)00391-9"},{"key":"2020021219282867700_REF15","doi-asserted-by":"crossref","unstructured":"Aggarwal BB. Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochem Pharmacol. 2000;60: 1033-1039.","DOI":"10.1016\/S0006-2952(00)00393-2"},{"key":"2020021219282867700_REF16","doi-asserted-by":"crossref","unstructured":"Stambolic V, Mak TW, Woodgett JR. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene. 1999;18: 6094-6103.","DOI":"10.1038\/sj.onc.1203126"},{"key":"2020021219282867700_REF17","doi-asserted-by":"crossref","unstructured":"Marte BM, Downward J. PKB\/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997;22: 355-358.","DOI":"10.1016\/S0968-0004(97)01097-9"},{"key":"2020021219282867700_REF18","doi-asserted-by":"crossref","unstructured":"Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Curr Oncol Rep. 2002;4: 20-28.","DOI":"10.1007\/s11912-002-0044-9"},{"key":"2020021219282867700_REF19","unstructured":"Brown LF, Tognazzi K, Dvorak HF, Harrist TJ. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor\/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol. 1996;148: 1065-1074."},{"key":"2020021219282867700_REF20","unstructured":"Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998;58: 1952-1959."},{"key":"2020021219282867700_REF21","unstructured":"Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55: 3964-3968."},{"key":"2020021219282867700_REF22","unstructured":"Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2: 1679-1684."},{"key":"2020021219282867700_REF23","unstructured":"Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59: 728-733."},{"key":"2020021219282867700_REF24","doi-asserted-by":"crossref","unstructured":"Gabrilove JL. Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies. Oncologist. 2001;6(suppl 5): 4-7.","DOI":"10.1634\/theoncologist.6-suppl_5-4"},{"key":"2020021219282867700_REF25","doi-asserted-by":"crossref","unstructured":"Wang Y, Pennock S, Chen X, Wang Z. Internalization of inactive EGF receptor into endosomes and the subsequent activation of endosome-associated EGF receptors. Sci STKE. 2002;161: L17.","DOI":"10.1126\/stke.2002.161.pl17"},{"key":"2020021219282867700_REF26","doi-asserted-by":"crossref","unstructured":"Sorkin A. Internalization of the epidermal growth factor receptor: role in signalling. Biochem Soc Trans. 2001;29: 480-484.","DOI":"10.1042\/bst0290480"},{"key":"2020021219282867700_REF27","doi-asserted-by":"crossref","unstructured":"Wells A, Marti U. Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol. 2002;3: 697-702.","DOI":"10.1038\/nrm905"},{"key":"2020021219282867700_REF28","doi-asserted-by":"crossref","unstructured":"Feng Y, Venema VJ, Venema RC, Tsai N, Caldwell RB. VEGF induces nuclear translocation of Flk-1\/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun. 1999;256: 192-197.","DOI":"10.1006\/bbrc.1998.9790"},{"key":"2020021219282867700_REF29","doi-asserted-by":"crossref","unstructured":"Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003;14: 334-347.","DOI":"10.1091\/mbc.e02-07-0379"},{"key":"2020021219282867700_REF30","doi-asserted-by":"crossref","unstructured":"Abumiya T, Sasaguri T, Taba Y, Miwa Y, Miyagi M. Shear stress induces expression of vascular endothelial growth factor receptor Flk-1\/KDR through the CT-rich Sp1 binding site. Arterioscler Thromb Vasc Biol. 2002;22: 907-913.","DOI":"10.1161\/01.ATV.0000018300.43492.83"},{"key":"2020021219282867700_REF31","doi-asserted-by":"crossref","unstructured":"Shay-Salit A, Shushy M, Wolfovitz E, et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci U S A. 2002;99: 9462-9467.","DOI":"10.1073\/pnas.142224299"},{"key":"2020021219282867700_REF32","doi-asserted-by":"crossref","unstructured":"Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2003;99: 2532-2540.","DOI":"10.1182\/blood.V99.7.2532"},{"key":"2020021219282867700_REF33","doi-asserted-by":"crossref","unstructured":"Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 2002;64: 883-888.","DOI":"10.1016\/S0006-2952(02)01154-1"},{"key":"2020021219282867700_REF34","doi-asserted-by":"crossref","unstructured":"Fiedler W, Mesters R, Tinnenfeld H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102: 2763-2767.","DOI":"10.1182\/blood-2002-10-2998"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/10\/3883\/1697683\/zh801004003883.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/10\/3883\/1697683\/zh801004003883.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T01:07:15Z","timestamp":1581556035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/10\/3883\/17667\/Internal-and-external-autocrine-VEGFKDR-loops"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,15]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-05-1634","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,15]]}}}